ENCLONY Takes Pharmaceutical Inspection Technology Global with High Speed Vision and Laser Automation

Pharmaceutical manufacturing was becoming increasingly dependent on automation, not simply to raise production volumes but to maintain consistent quality at industrial scale. Against this backdrop, South Korean technology company ENCLONY was expanding its international footprint with automated vision inspection systems designed specifically for tablets and capsules.

Founded in 2013, ENCLONY had built its business around machine vision technology that enabled pharmaceutical manufacturers to inspect products automatically during production. Its expansion across North America, Europe and Japan reflected a broader shift in the industry towards integrated quality control, where inspection was becoming part of the manufacturing process rather than a separate final stage.

Turning Inspection into an Automated Process

At the heart of ENCLONY’s portfolio was its PLANET EV series, a high speed inspection platform designed to capture tablets and capsules from multiple angles while they moved through production lines. The system automatically identified a range of defects, including foreign particles, broken tablets, discolouration, printing errors and surface irregularities. For pharmaceutical manufacturers operating at large volumes, that level of automation offered an important combination of speed and consistency.

ENCLONY had also moved beyond conventional inspection by combining laser printing with automated vision technology. Its integrated solutions enabled manufacturers to mark identification information directly onto tablets while simultaneously checking the quality of the printing and the physical appearance of the product.

That combination was significant. Rather than treating identification, printing and inspection as separate processes, manufacturers could integrate them into a single automated workflow.

As pharmaceutical production becomes increasingly sophisticated, the ability to connect individual stages of manufacturing has become an important part of the sector’s digital transformation. The wider healthcare industry has similarly been moving towards technology driven systems that improve efficiency, traceability and quality. For more perspectives on business and technology trends, WEM India covers developments shaping India’s rapidly evolving business landscape.

A Growing International Client Base

ENCLONY’s technology had already gained traction among major pharmaceutical companies. Its international client portfolio included global names such as Pfizer, Johnson & Johnson, AbbVie and Viatris, along with Japanese pharmaceutical major Eisai.

Japan was an important market in the company’s international strategy. Through its local subsidiary, Nippon ENCLONY, the company strengthened sales and technical support while maintaining a presence through its Osaka showroom.

Europe represented another important growth market. ENCLONY GmbH was supporting the company’s European operations and helping it work more closely with global pharmaceutical customers in the region.

The strategy reflected a practical reality of industrial technology. Sophisticated equipment requires more than a product catalogue. Customers also need technical assistance, application support and reliable service close to their manufacturing operations.

High Speed Inspection for Mass Production

ENCLONY’s technology was designed to operate at substantial production speeds. Its inspection platform was capable of examining as many as 425,000 tablets per hour, positioning the technology for high volume pharmaceutical manufacturing environments.

Speed, however, was only one part of the proposition.

The company continued to focus on inspection flexibility across different product types, ease of operation and integration with existing manufacturing lines. For pharmaceutical producers, these factors can determine whether automation delivers genuine operational value or simply adds another layer of complexity to an already sophisticated production environment.

The company’s approach also reflected a larger trend in industrial manufacturing. Automation is increasingly being judged not only by how quickly a machine performs a task, but by how effectively it communicates with the wider production ecosystem.

Taking the Technology to Global Markets

ENCLONY had continued to use international industry exhibitions as an important part of its expansion strategy. At Interpack 2026 in Düsseldorf, Germany, the company presented its tablet and capsule inspection systems alongside its integrated laser printing and inspection solutions.

Such exhibitions provide industrial technology companies with an opportunity to demonstrate complex equipment to potential customers who may otherwise require lengthy technical evaluations before making purchasing decisions.

For ENCLONY, the international exhibition strategy complemented its growing network of subsidiaries and customer relationships.

The company said automated inspection technology was becoming increasingly important as pharmaceutical manufacturers sought to balance productivity with stringent quality requirements. Its accumulated experience in machine vision and pharmaceutical production was being used to develop systems aimed at meeting those demands directly on the factory floor.

Building the Next Stage of Global Growth

ENCLONY’s expansion came at a time when pharmaceutical manufacturers worldwide were under pressure to improve efficiency while maintaining increasingly demanding quality standards. Automated inspection offered one route towards addressing both requirements.

The company’s focus on machine vision, high speed inspection and integrated laser printing placed it at the intersection of pharmaceutical manufacturing and industrial automation.

Its strategy was also becoming increasingly localised. Strengthening support in markets such as Japan and Europe suggested that global expansion was not being approached simply through exports, but through closer customer engagement and regional infrastructure.

That distinction could become increasingly important as pharmaceutical manufacturing becomes more automated and connected.

ENCLONY had started with a specialised technology focused on inspecting tablets and capsules. It was now building a broader international proposition around that expertise, combining inspection, identification and automation into increasingly integrated production solutions.

For a company operating in a sector where precision is fundamental, the direction was clear. The future of pharmaceutical manufacturing was not only about producing more. It was about producing more consistently, intelligently and with greater control.